U.S. markets open in 2 hours 28 minutes

Amgen Inc. (0R0T.L)

LSE - LSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
243.76-3.37 (-1.36%)
A partir del 06:01PM GMT. Mercado abierto.

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(es)
Industria
Empleados a tiempo completo26,700

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Robert A. BradwayChairman, CEO & President5.49MN/D1963
Mr. Peter H. GriffithExecutive VP & CFO2.57MN/D1959
Mr. Esteban SantosExecutive Vice President of Operations2.52MN/D1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer2.83MN/D1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations2.72MN/D1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceN/DN/D1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerN/DN/DN/D
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerN/DN/D1972
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2.44MN/D1961
Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and Chief Compliance OfficerN/DN/D1968
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Amgen Inc. a partir del 28 de febrero de 2024 es 3. Las puntuaciones principales son Auditoría: 4; Junta: 9; Derechos del accionista: 1; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.